Introduction
The Human Genome Project has generated hope and expectations of improving the quality of care and of using genetic information to predict response to drugs. It has led some to make the optimistic claim that the development of 'personalized' medicine, or of 'the right medicine, for the right patient, at the right dose', is only a matter of time. Pharmacogenetics studies the effects of genetic differences between individuals and their different responses to the same drug, given the differences existing in pharmacokinetic and pharmacodynamic factors. 1 In fact, genes may potentially Preliminary pharmacogenetic data suggest that germline genetic informations might be of value in individualizing disease-modifying antirheumatic drugs (DMARDs) therapy in various autoimmune chronic inflammatory diseases. Either DMARDs small molecules (DMARDs-SM) or DMARDs biological therapies (DMARDs-BT) might be selected for their lower toxicity or better efficacy based on single-nucleotide polymorphisms (SNPs) of genes governing the metabolism of drugs, or the response of immune cells to proinflammatory molecules, or the proinflammatory molecular activity of immune cells. Data available for one DMARDs-SM, methotrexate, suggest that a careful assessment of the SNPs of four enzymes involved in the folate metabolism allow one to construct a genetic index of toxicity (toxicogenetic index) that might be employed in daily practice to find the patient's most at risk. Only the full knowledge of the various gene polymorphisms controlling the phenotypic manifestations of the inflammatoryimmunological milieu of each rheumatic disease will allow one to obtain the clear definition of a personalized medicine. Few different cytokine gene SNPs seem to be of importance in determining the susceptibility to diseases, or the aggressiveness of diseases. The role of genetics in affecting a possible clinical response to DMARDs-BT targeting specific inflammatory molecules or their receptors still has to be defined. However, the available data suggest that cytokine (and/or receptors) gene SNPs might indeed play a role in determining the biological effects, hence the clinical effectiveness of DMARDs-BT. Crucial to this aim will be the prospective analysis of clinical benefits and safety on the basis of the at baseline stratification of gene SNPs in each chronic inflammatory rheumatic disease before starting any new DMARDs-SM or DMARDs-BT.
affect any of the proteins involved in drug absorption, metabolism and excretion. Along this line, pharmacogenetics has the potential to play an important role in improving the safety and efficacy of several drugs. 2 The relevance of polygenicity in rheumatic autoimmune chronic inflammatory diseases All autoimmune chronic inflammatory diseases (ACIDs) are polygenic diseases in which the persistence of chronic inflammation targets various organs and apparatus. [3] [4] [5] In ACIDs, several genes determining the synthesis of dozen of molecules involved in gene expression (transcription factors), cell activation (cytokines) and cell signalling (receptors) are usually involved. Many of these genes carry single-nucleotide polymorphisms (SNPs), some of which have been discovered to be functionally relevant. 6 Any one of these genes could theoretically play an important role in the phenotypic manifestations of the disease. 7, 8 Clinically, a phenotypic character could determine different responses to the same therapeutic approach. An example is the erosive phenotype of rheumatoid arthritis (RA), the most aggressive and joint destructive among all the chronic arthritides. It is recognized that being erosive means remaining erosive despite any therapy with disease-modifying antirheumatic drugs small molecules (DMARDs-SM), including methotrexate -(MTX), leflunomide (LFN), sulphasalazine (SSZ), Cyclosporin (CsA), gold salts (GS), in the great majority of the cases, and means of having a poor prognosis over time. [9] [10] [11] In these cases, genes leading to such an aggressive phenotype impact very strongly any type of therapy. Other genes influence metabolism, transport, excretion or pharmacodynamic characteristics (different responses to the same drug concentration). Very different outcomes could then be envisioned in patients having the same aggressive phenotype. For example, patients undergoing long-term ther-apy with MTX experience various side effects, but the risk increases proportionally to the genotypes of the four major folic acid pathway enzymes (methylene tetrahydrofolate reductase (MTHFR), thymidylate synthase (TSER), AICAR transformylase (ATIC), serine hydroxymethyltransferase (SHMT)). 12, 13 Weisman et al. 14 investigated whether risk genotypes for folate-dependent enzymes were associated with the occurrence of side effects in a cohort of RA patients treated with MTX for at least 1 month, and they found that patients carrying an increasingly toxicogenetic index, made of single SNPs of each enzyme (MTHFR677TT þ TSER*2/2 þ ATIC347GG þ SHMT1 1420CC), had a progressive increase of the risk. These variables could be systematically invoked in all ACIDs and they could partially explain why, even the most powerful among the various antirheumatic drugs, the disease-modifying antirheumatic drugs biological therapies (DMARDs-BT), which are directed against specific target molecules of chronic inflammation or of the immune activation, are not universally efficacious. Studies suggest that up to one-third of the patients do not respond to these treatments. In these cases, it is important not only to start DMARDs therapy early on in the course of the disease but also to select a DMARD, considering the genetic and immunological profile of the single patient for a better response to treatment. It is not known why some patients respond better to therapy than others, nor why some patients respond to one DMARDs but not to others. This heterogeneity in drug response is likely to be a result of both individual patient factors (environmental and genetic) and disease-specific factors. 15 In the rheumatological field, given the great advances in pharmacotherapy and the introduction of very expensive biological drugs, a strategy leading to the early identification of the 'best responder patient' to any of the various molecules or eventually of those subjects presenting side effects to the various drugs is strongly pursued. The study of gene polymorphisms of cytokines, receptors of cytokines, drug carriers or other relevant molecules might form the basis of a full screening methodology, allowing one to personalize the drug intervention with the various molecules available in the therapeutic armamentarium. In this review, we will focus on:
Genetic and pathophysiology of the major chronic arthritides. The relevance of the human leukocyte antigen (HLA) of the major histocompatibility complex (MHC) region on chromosome 6 in determining the immunological phenotype of the major disease entities, that is, RA and seronegative spondyloarthropathies (SNeSPA). The prevalence of various gene polymorphisms so far described in the literature in RA, or when available in SNeSPA, regarding genetic predictors of drug response or molecules implicated as specific drug targets.
Etiology and genetics of rheumatoid arthritis
Rheumatoid arthritis is a chronic inflammatory usually destructive disease affecting the diarthrodial joints. The RA target tissue is the cartilage (and the subchondral bone), which is progressively eroded, whereas the effector tissue is the synovial membrane, which normally produces the lubricating molecules responsible for the maintenance of the normal gliding of the opposing cartilages. In arthritic patients, this membrane becomes infiltrated by inflammatory-immune cells (macrophages, T-and B-lymphocytes, dendritic cells, mast cells) and behaves like a tumor-like tissue with invasive and locally metastatizing properties. 16 In addition to these features, the SNeSPA present inflammation also at the insertion of tendons, the so-called enthesis, thus presenting inflammation and erosions also at the tendon insertion to the periostal bone. 17 The immune-inflammatory cells migrate to the synovial tissue being attracted there by chemokines (molecules driving the movement of immune cells from the bloodstream to tissues), and once in the tissue, they organize themselves into various histopathological structures (diffuse pseudogranulomatous and pseudogerminal centre like follicular infiltration). 18 The histopathological pattern is similar in the various joints. This means that there is likely a genetic component predisposing to the tissue pathology. In the synovial tissue, macrophages, synovial fibroblasts, dendritic cells and B cells are efficient antigen-presenting cells and they can present antigens to the T cells that are activated and present clear evidence of autoreactivity against several potential autoantigens. The B cells also show evidence of clonal selection owing to (auto)antigen-induced expansion, 19 and the macrophages along with synovial fibroblasts upon activation secrete molecules capable of destroying the components of the cartilage and the subchondral bone, thus leading to erosions of the joints. 20 The autoreactivity of the immune inflammatory cells is determined by the HLA complex, a genetic region in chromosome 6 also known as the MHC, which controls the immune response against exogenous as well autologous antigens. The HLA complex occupies a 3.6 Mb region of the short arm of chromosome 6 (6p21.3) made of about 220 defined genes. 21 Within the MHC, a further possible candidate for RA susceptibility is the tumour necrosis factor (TNF) locus. In fact, when addressing the issue of haplotype analysis in a set of 469 multicase families with RA, two additional genetic effects within the MHC were found. One was seen in the central region (497 kb) of the HLA complex, and this region was found to be the ancestral 8.1 (A1.B8.DRB1*3) haplotype. This is consistent with studies reporting that marker alleles in the TNF region may be associated with RA 22 and that the RA-associated TNF alleles may be found on a DRB1*03 haplotype. 23 The second result was the demonstration of a genetic effect within the class II region of some DRB1*0404 haplotypes. In particular, it was shown that while the DRB1*0404 allele per se confers a relatively modest risk, the heterozygote DRB1*0401/*0404 displays a very high risk (relative risk (RR) ¼ 19.32, 95% confidence interval (CI) ¼ 6-63).
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Human leukocyte antigen complex, outside HLA regions and course of the disease Autoimmune chronic inflammatory diseases have shown a relationship with alleles or haplotypes of the HLA system. Rheumatoid arthritis associates with the shared epitope (SE) of HLADRB1, a conserved sequence of amino acids encoded by the HLA-DRB1*0401, *0404, *0405, *0408, *0101, *1001 and *1402 alleles. Gregersen showed that the DRB1 alleles of the DR molecule had common sequences in their third hypervariable region, in particular a sequence 72-74 with the RAA motif was shared among all the alleles. 24, 25 Later the associated sequences were shown to be from position 70-74 (QKRAA, QRRAA, RRRAA). Following Gao's proposal, 26 du Montcel et al. 27 proposed a new classification based on the hypothesis that amino acids at position 70 or 71 could confer a different risk when coupled with the common RAA sequence. Indeed, she demonstrated that given the role of the RAA sequence (72-74), a lysine (K) at position 71, thus the sequence KRAA at position 71-74, confers the highest risk, with a lower risk in sequence made by the sequences RRRAA and QRRAA. These data could allow to categorize the RA population and the course under treatment at the onset of the disease.
A whole-genome scan using 11 245 SNPs compared to microsatellites, performed in 157 families with multiple cases of RA 28 detected HLA*DRB1 as the major susceptibility locus for the disease, showed clearly that SNPs provided significantly higher information than the microsatellites and demonstrated that the technology of a dense SNP map for performing linkage analysis could allow to define involved loci much more precisely. Specifically, RA has been associated with the SE of HLA-DRB1; 29 the RA patients with the SE had more frequently a severe disease, indicating not only an association with disease susceptibility but also an influence on disease severity. 30 The wholegenome scan of families with multiple cases of RA have revealed some other leading genomic regions possibly linked to RA, located in chromosomes 1p13 and 18q21. 31, 32 The most recent discovery is the confirmed association between a variant (1858C to T and encoding R620W) of the intracellular protein tyrosine phosphatase N22 (PTPN22) and seropositive RA. 33 As far as regions of chromosome 1 are concerned, a French group addressed the role played by the SE and by the TNFa receptor 2 gene polymorphism (TNFRII SNP -196 M/R) as a genetic risk of future development of RA in a cohort of patients with early undifferentiated arthritis. 34 Interestingly, patients developing RA had a low association with the SE (P ¼ 0.051, odds ratio (OR) ¼ 35 Another gene outside the HLA system was studied by Spanish investigators, 36 who have provided data to support the role of the interleukin (IL)1 gene cluster in the predisposition to develop RA. In particular, with regards to the IL1 receptor antagonist (IL1RN) gene, it is known that there is an SNP in the IL1RN intron 2, which is generated by a variable number of copies of an 86 base pair (86 bp) tandem repeat (VNTR). The frequency and the carriage rate of allele 2 (IL1RN*2) of the IL1RN-VNTR was significantly increased in RA compared to healthy controls. The conclusion was that the IL1RN plays a role in influencing susceptibility to RA in the Spanish population.
Aetiology and genetics of seronegative spondyloarthropathies While RA associates with alleles of class II of the HLA system, SNeSPA instead associate with HLA-B27, which is found in 95% of European patients with ankylosing spondylitis (AS), 37 70% with reactive arthritis (ReA), 38 60% with psoriatic spondylitis, 25% with peripheral psoriatic arthritis (PsA), 70% with spondylitis associated with inflammatory bowel disease. 39 Family studies have suggested that HLA-B27 contributes only about 37% of the overall genetic risk for SpA. 40 The entire effect of the MHC is about 50%. In addition in white English patients, strong linkage disequilibrium is present between B27 and DR1, 41 whereas in German patients B27 is linked to DR4. 42 The North American Spondylitis Consortium examining multicase families with AS has so far implicated, in addition to the MHC, regions on chromosome 6q and 11q, along with other regions on chromosomes 1q, 3q, 5q, 10q, 16q, 17p and 19q. 43 A weak association of AS was found with the VNTR in intron 2 of the IL1 receptor antagonist (IL1RN) in two studies from Scotland and the Netherlands, 44 and with an SNP of CYP2D6, a gene found on chromosome 22q, which encodes a protein involved in the metabolism of xenobiotics, which contribute to T-cell-related inflammation. The poor metabolizer 'pm' genotype associated weakly with AS in German and British patients. 45, 46 Genetics and disease-modifying antirheumatic drugs effectiveness The DRB1 SE is the major predisposing factor to RA, and it also arose as the best genetic predictor of response to DMARDs-SM in RA. O'Dell et al. 47 observed that the SE-positive RA patients responded better to the triple therapy with MTX-SSZ-hydroxychloroquine compared with MTX alone (94% responders vs 32%, Po0.0001). These data were confirmed by our group in a cohort of Mediterranean patients with RA. We showed that while MTX monotherapy gave poorer results in DR4/DR1-positive patients (American College Rheumatology 50% improvement (ACR50), 29 vs 80% in DR4/DR1-negative patients), CsA monotherapy was more effective in the DRY-DR1 subjects (ACR50, 52 vs 6% in DR4/DR1-negative patients) 48 and Gonzales-Gay et al. 49 found that RA patients carrying the HLA-DRB1*0401/0404 developed a severe disease and needed more frequently a combination of MTX and CsA therapy.
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Interestingly, Criswell et al. 50 followed a group of 632 RA patients with an early active disease (duration p3 years) for 12 months treated with standard doses of etanercept (fusion protein of immunoglobulin G1 directed against the p75 receptor of TNFa) (10 mg twice weekly) compared with MTX. They showed that patients who had inherited two copies of SE achieved a better improvement when biologicals (DMARDs-B) were taken into account (greater than 50% improvement of clinical and laboratory variables compared to baseline) (called the American College Rheumatology 50% improvement). On the other hand, Martinez et al. 51 followed 78 patients with RA for 3 months during Infliximab treatment and they found no differences in SE carrier rate in responders and non-responders to the therapy (71% in responders and 64% in non-responders).
These data only suggest that RA patients carrying the SE have a more severe disease and they will likely need combination therapy including also the new biological drugs.
Cytokine plasma levels, cytokine gene setting and tumour necrosis factor a gene complex in rheumatoid arthritis and seronegative spondyloarthropathies Tumour necrosis factor a and tumour necrosis factor b (TNF b or lymphotoxin a, LTA) are proinflammatory cytokines that play a central role in the pathogenesis of RA and spondyloarthritis, even if it is controversial whether their genes are associated with RA. 52 A cytokine pattern characterized by a downregulation of proinflammatory cytokines as TNFa, IL1b, IL6 and interferon (INF)g with respect to regulatory or immunosuppressive cytokines as IL4, IL10 and TGFb, was reported in AS, PsA, ReA, arthritis associated with inflammatory bowel disease and undifferentiated forms than RA. 53 Bacterial infections with possibly subsequent crossreactivity to autoantigens are believed to be triggering events in the pathogenesis of spondyloarthropathies, and it has been suggested that impaired Th1 cytokine response might account for the failure of the immune system to eliminate the infectious agent. Other studies about cytokine profiling in spondyloarthropathies report a global expression of proinflammatory cytokines similar to RA. 54 These data could explain the beneficial effect of TNFa blockers both in AS and PA. 55 Conflicting data have been reported on the effect of the anti-TNF treatment on cytokine profiles in spondyloarthropathies: the pattern of cytokines in synovial inflammation or enthesopathy may not be reflected by serum levels. 56 Furthermore, it will be necessary to investigate how the presence of cytokine polymorphisms influence the response to treatment.
Significantly higher serum, synovial fluid and synovial membrane levels of proinflammatory cytokines (IL1, IL6, IL8 and TNFa) and anti-inflammatory cytokines (IL1Ra, IL10) have been found in PsA than in control patients without inflammatory disease and in healthy controls. [57] [58] [59] Similar results were found in AS. 60, 61 A Th2 cytokine pattern (low TNFa, low INFg and high IL-10) has been observed in the joints of patients with ReA and low TNFa secretion by peripheral blood mononuclear cells (PBMC) in these patients has been associated with a chronic disease course, 62 whereas patients with high T-cell secretion of TNFa at disease onset experienced a short and selflimiting course of the disease. 63 In chronic ReA, TNFa production was higher than in acute disease, suggesting that the Th1 response in chronic ReA is more dominant than that in acute ReA. 64 These data suggest that anti-TNFa therapy may be an effective treatment also in chronic ReA.
The success of novel therapeutic agents such as anticytokine antibodies, ILs and anti-T-cell therapies, which specifically block cytokine effects, provides further evidence of the central role of cytokines in inflammation in spondyloarthropathies, 65, 66 but interestingly a decreased production of TNFa from PBMCs after stimulation was found in patients with PsA more than in patients with psoriasis. 67 Several microsatellites around the TNF gene locus, SNPs of TNF promoter and MHC class II genes have been found to influence TNFa secretion. An association of TNF-238A with psoriasis and PA and a decreased production of TNFa in association with this promoter variant 68 have been described, but conflicting studies in spondyloarthropathies were reported. An increased frequency of TNF-238A in psoriasis and PA was found in two studies in Western European white populations, 69 ,70 but was not confirmed in patients with PA in an English 71 and Estonian studies. 72 An investigation from Germany found a decrease in TNF-238A in AS, which was not seen in other studies: in Kaijzel et al. 73 and Gonzalez et al. studies, the frequency of TNF-238A was significantly decreased only with respect to healthy subjects HLA-B27 negative and to patients with AS HLA-B27 negative, respectively. In addition, a Dutch study found no difference in the transcriptional activity of the TNF-238A variant in RA population. 74 TNF-238A is part of the ancestral haplotype, TNF-238A-B57-Cw6, which shows the strongest disease association with psoriasis and it is difficult to calculate the relative disease contribution. An HLA-B27-independent association of the TNFa6c1d3 haplotype with PA and an association of the a6 allele with decreased secretion of TNFa independent of TNF-238A were also found. TNFa6 was also found to be associated with ReA in HLA-B27-positive Finnish patients, whereas in patients with AS, no difference was observed in the allele distribution. 75 How this genetically determined low TNFa production might be important for the development of arthritis in patients with psoriasis is not clear. In fact, the importance of bacterial persistence for the development of PA has not been formally shown. 76 Furthermore, higher TNFa levels seem to associate with disease severity and progression: the allele A of TNFa À308 and the allele B1 of TNFb þ 252, which are in linkage disequilibrium and associated with higher levels of TNFa and TNFb (LTA), were found with higher frequency in PA patients with erosions and disease progression, even though no different frequencies were found between patients and controls. 77 
This was
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G Ferraccioli et al 6 The Pharmacogenomics Journal confirmed by Mossner et al's. study in which TNF-308A appeared increased in subjects with more severe joints disease. In this study and in Hohler et al., a significant decrease of the À308A allele in the PA group was found, but with no significant effect on TNFa production was observed. A link with TNF-308G independent of HLA-B27 was found in a large analysis of patients with AS, 78 but was not confirmed by a study including patients from a larger geographical area. 79 Conflicting results have been also reported about transcriptional activity of TNF-308A. Different explanations are likely: some studies were performed in patients carrying HLA-B27, which is linked to lower TNFa production; 63 in fact, it has been shown that TNF-308A allele is associated with high TNFa production only in HLA-B27-positive individuals, thus suggesting that HLA-B27-associated mechanism mediates the effect of the polymorphism. 53 Furthermore, TNF-308A is part of the A1 B8 DR3 haplotype, which is also linked to high production of TNFa. 80 Its proximity to the MHC raises the possibility that any variations within the TNF locus are present simply because of linkage disequilibrium with the MHC (Table 1) . The close association with the MHC necessitates studies to tease out any direct links with the various TNF polymorphisms in the absence of associations with the extended haplotypes. Studies in vitro and investigation on mRNA transcription cannot clarify the role of the different polymorphisms in regulating TNFa production. Different data from in vitro culture experiments using PBMCs could be explained by the different stimulus applied, although the promoter region for TNFa is identical, the regulatory sequences may respond differently in monocytes than T cells. Furthermore, many studies are performed in individuals not homozygous at the loci of interest, so it is difficult to quantify the influence of an allele. Unfortunately, the analysis of mRNA production failed to explain the genetic control of TNFa probably because a double hit, near TNFa gene or in linked region, is necessary to control protein synthesis. Despite these problems, it is clear that TNFa production is under genetic control, that the role of the different polymorphisms or haplotypes and the role of the interaction of polymorphisms in determining TNFa levels, predisposition and course or clinical manifestation of spondyloarthropathies nor the therapeutic response has not been clarified. No studies investigated the response to biologic drugs in relation to other cytokine gene polymorphisms beside TNFa.
Perspectives
The advent of biological response modifiers, like TNF-a blockers, offers a unique opportunity to test a genetic setting predisposing either to a favourable response or to adverse drug actions. Genotyping patients for TNFa haplotype and TNFRII gene polymorphisms should be carried out in all future trials, and the assessment of the clinical response made according to the clinical, immunological prognostic factors, but most importantly after stratifying the patients on the basis of their defined genotype.
